vs
Side-by-side financial comparison of Webull Corp (BULL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Webull Corp is the larger business by last-quarter revenue ($131.5M vs $70.6M, roughly 1.9× Viridian Therapeutics, Inc.\DE). Webull Corp runs the higher net margin — -21.5% vs -49.0%, a 27.5% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 46.3%). Webull Corp produced more free cash flow last quarter ($271.7M vs $-84.7M).
Webull Corporation, often stylized as simply Webull, is a US-based financial services holding company headquartered in St. Petersburg, Florida. It provides an electronic trading platform of the same name.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
BULL vs VRDN — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.5M | $70.6M |
| Net Profit | $-28.3M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | -16.3% | -56.7% |
| Net Margin | -21.5% | -49.0% |
| Revenue YoY | 46.3% | 81958.1% |
| Net Profit YoY | -144.3% | 54.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $70.6M | ||
| Q2 25 | $131.5M | — | ||
| Q2 24 | $89.9M | — |
| Q3 25 | — | $-34.6M | ||
| Q2 25 | $-28.3M | — | ||
| Q2 24 | $-11.6M | — |
| Q3 25 | — | -56.7% | ||
| Q2 25 | -16.3% | — | ||
| Q2 24 | -11.4% | — |
| Q3 25 | — | -49.0% | ||
| Q2 25 | -21.5% | — | ||
| Q2 24 | -12.9% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $476.7M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $751.6M | $503.0M |
| Total Assets | $2.6B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q2 25 | $476.7M | — | ||
| Q2 24 | — | — |
| Q3 25 | — | $503.0M | ||
| Q2 25 | $751.6M | — | ||
| Q2 24 | $-2.9B | — |
| Q3 25 | — | $577.1M | ||
| Q2 25 | $2.6B | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $272.1M | $-84.6M |
| Free Cash FlowOCF − Capex | $271.7M | $-84.7M |
| FCF MarginFCF / Revenue | 206.6% | -120.1% |
| Capex IntensityCapex / Revenue | 0.3% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q2 25 | $272.1M | — | ||
| Q2 24 | — | — |
| Q3 25 | — | $-84.7M | ||
| Q2 25 | $271.7M | — | ||
| Q2 24 | — | — |
| Q3 25 | — | -120.1% | ||
| Q2 25 | 206.6% | — | ||
| Q2 24 | — | — |
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.3% | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
